

REMARKS

It is respectfully requested that this Preliminary Amendment be entered in this application prior to examination. Early and favorable consideration is requested.

Respectfully submitted,



Frank S. DiGiglio
Registration No. 31,346

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

PIB:bb

FOST-4262660

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Page 1, after the title, please insert the following:

--CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a divisional of application Serial Number 09/368,632 filed August 5, 1999.--

IN THE CLAIMS:

Please cancel Claims 1-20 and 22-28 before calculating the filing fee of this divisional application.

Please amend Claim 21 as follows:

21. (Amended) A pharmaceutical composition comprising the antibody of [Claim 19] any one of Claims 29-35.

Please add the following new Claims:

29. (New) An antibody directed against an isolated IL-16 antagonist peptide consisting of CLLS (SEQ ID NO:2).

30. (New) An antibody directed against an isolated IL-16 antagonist peptide consisting of any one of WQCLLS, WQALLS, VVQVVA or VKQVVA.

31. (New) An antibody directed against an isolated IL-16 antagonist peptide consisting of GMWQLLS (SEQ ID NO:13).

32. (New) An antibody directed against an isolated IL-16 antagonist peptide consisting of GMWQCLLSDSGQVLLE (SEQ ID NO:12).

33. (New) An antibody directed against an isolated IL-16 antagonist peptide consisting of TGLWQCLLSEGD (SEQ ID NO:14).

34. (New) An antibody directed against an isolated IL-16 antagonist peptide consisting of VSEEQKVVQVVA (SEQ ID NO:15).

35. (New) An antibody directed against an isolated IL-16 antagonist peptide comprising Xaa₁-L-L-Xaa₂ wherein Xaa₁ and Xaa₂ is any amino acid (SEQ ID NO:1).

105130-126260